170,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
Melden Sie sich für den Produktalarm an, um über die Verfügbarkeit des Produkts informiert zu werden.

  • Broschiertes Buch

Protein Misfolding in Neurodegenerative Diseases is a comprehensive review of proteome homeostasis in neurons, and in the brain. Beginning with an introduction on factors involved in the formation and aggregation of misfolded proteins, chapters then discuss the precise cellular and molecular mechanisms involved in these processes and their role in neurodegeneration and disease. Additional topics of focus include protein clearance mechanisms like protein quality control, disease-modifiers, molecular druggable targets, novel therapeutics, and emerging techniques that block or delay disease onset…mehr

Produktbeschreibung
Protein Misfolding in Neurodegenerative Diseases is a comprehensive review of proteome homeostasis in neurons, and in the brain. Beginning with an introduction on factors involved in the formation and aggregation of misfolded proteins, chapters then discuss the precise cellular and molecular mechanisms involved in these processes and their role in neurodegeneration and disease. Additional topics of focus include protein clearance mechanisms like protein quality control, disease-modifiers, molecular druggable targets, novel therapeutics, and emerging techniques that block or delay disease onset or progression. This volume is relevant for researchers working with neurodegenerative diseases, including Alzheimer's disease, Parkinson’s disease, ALS, Creutzfeldt-Jakob disease, and more.
Autorenporträt
Dr. Gogia is a Post-Doctoral Associate at Yale. Having completed her PhD degree at the University of Dayton, and Cornell University's International Agriculture and Rural Development Program (IARD) she was awarded the Gerald L. Willis Award of Excellence for Outstanding Teaching in 2019. Her current work focuses on understanding cellular and molecular mechanisms underlying polyglutamine diseases, namely the identification and validation of genetic modifiers which can serve as potential therapeutic targets and can ameliorate the onset or progression of neurodegenerative diseases.